Thank you!

Your quote has been successfully submitted!

For products requiring additional information, our team will contact you within 1 business day

Failed

There was an error submitting your quote. Please try again.

MSE PRO 5,6-Dihydro-1H-imidazo[1,2-a]imidazole, 97.0% Purity– MSE Supplies LLC

Free Shipping on MSE PRO Online Orders of $500 or More! U.S. Orders Only * Offer Excludes Hazmat Shipments *

Menu
Cart

This product has been added to the cart.

MSE PRO 5,6-Dihydro-1H-imidazo[1,2-a]imidazole, 97.0% Purity - MSE Supplies LLC

MSE PRO 5,6-Dihydro-1H-imidazo[1,2-a]imidazole, 97.0% Purity

SKU: CM1344

  • $ 81995

MSE PRO™ 5,6-Dihydro-1H-imidazo[1,2-a]imidazole, 97.0% Purity

MSE PRO™ 5,6-Dihydro-1H-imidazo[1,2-a]imidazole is a unique small molecule building block within the imidazoline family. Imidazoline and its derivatives have demonstrated a broad range of therapeutic potentials including:

  • Analgesic and anti-inflammatory effects
  • Antidiabetic properties
  • Neuroprotective and anticonvulsant actions
  • Anticancer activity against various cancer cell lines

MSE Supplies offers various N-heterocyclic drug small molecules. Please contact us for bulk orders.

Technical Specifications:

CAS No. 67139-08-6
Chemical name 5,6-Dihydro-1H-imidazo[1,2-a]imidazole
Synonym(s)
  • 1H,2H,3H-[1,3]Diazolo[1,2-a]imidazole
  • 2,3-Dihydro-1H-imidazo[1,2-a]imidazole
Molecular formula C5H7N3 
Pack size

1 g (CM1344)
Molecular weight 109.13 g/mol
Melting point 122-125 °C 
Density  1.43±0.1 g/cm3 (Predicted)
Purity 97.0%
pKa
 		9.90±0.20 (Predicted)
Appearance Light yellow solid
Storage  2-8 °C, protected from light


References:

[1] Bousquet, P., Hudson, A., García-Sevilla, J. A., & Li, J. X. (2020). Imidazoline receptor system: The past, the present, and the future. Pharmacological Reviews, 72(1), 50-79.

[2] Head, G. A., & Mayorov, D. N. (2006). Imidazoline receptors, novel agents and therapeutic potential. Cardiovascular & Hematological Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Cardiovascular & Hematological Agents), 4(1), 17-32.